RET

Across TCGA pan-cancer cohorts, RET Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated RET data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RET Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RET expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

ACC, UCEC, and SCLC are the cancer types where RET Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.889	0.302	.013	22	view →
SCLC	OS	Median	All	0.055	0.653	<.001	21	view →
SARC	DFS	Median	All	0.101	0.632	.011	9	view →
STAD	OS	Median	III,IV	1.000	0.335	.038	7	view →
LGG	OS	Median	All	0.529	0.900	<.001	6	view →
PRAD	DFS	Median	All	0.106	0.776	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	DFS	Median	III,IV	1.000	0.538	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RET–ACC (DFS)

Open the ACC breakdown →